Further investigation into LUCAT1-mediated regulatory networks could pave the way for novel therapeutic strategies aimed at targeting resistant tumor cell populations and improving treatment efficacy in bladder cancer. This evidence concerns the gene LUCAT1 and urinary bladder carcinoma.